-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lilly has entered into research partnerships and exclusive licensing agreements with Precision BioSciences to use genome editing to develop treatments for genetic diseases.
the main plan and initial focus of the agreement, which also involves two other unrealed genetic targets, will focus on Duchy muscular dystrophy (DMD).
Lilly will conduct research and development using Precision's ARCUS genome editing platform, which comes from a natural genome editing enzyme called I-Crel that can be used for potential in vivo therapies for DMD and other genetic diseases.
as part of the deal, Precision will receive an upfront payment of $100 million and Lilly will invest $35 million in Precision's common stock.
, Precision is eligible for commercial milestone payments of up to $420 million per product.
, Precision will lead preclinical research and IND support activities, while Lilly will assume responsibility for clinical development and commercialization.
will also have the right to select up to three additional genetic targets for this partnership.
muscular dystrophy is a quite serious sexual cogenesiary muscle loss disorder.
male patients develop symptoms of muscle weakness from about the age of 4, after which the symptoms begin to deteriorate rapidly.
usually begins to atrophy from the thighs, the pelvic muscles, followed by the upper arm muscles.
。
